Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 9/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 4/20 | 0.41 |
| ▸ | AXL | P30530 | 5/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | SPR | P35270 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9906850 | 0.80 | CYP3A4 (0.40) | MAP4K1CYP3A4ABL1BRAFAXL | |
| SCHEMBL10029796 | 0.79 | PIK3CA (0.47) | MAP4K1CYP3A4ABL1AXLAAK1 | |
| SCHEMBL10029804 | 0.73 | KDM4E (0.36) | SPR | |
| SCHEMBL1772956 | 0.69 | MAP3K11 (0.39) | MAP4K1CYP3A4ABL1BRAF | |
| SCHEMBL9906846 | 0.69 | JAK2 (0.39) | MAP4K1CYP3A4ABL1AXL | |
| SCHEMBL30735555 | 0.69 | MAP4K1 (0.41) | MAP4K1CYP3A4ABL1BRAFSPR | |
| SCHEMBL18720827 | 0.69 | JAK3 (0.42) | — | |
| SCHEMBL14197017 | 0.69 | CYP2D6 (0.43) | MAP4K1CYP3A4ABL1 | |
| SCHEMBL1772830 | 0.67 | KIT (0.39) | — | |
| SCHEMBL10269012 | 0.67 | MET (0.43) | AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106069-B2 | Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2012-01-31 | — | — | US | disclosed |
| US-20100210476-A1 | Pyrrolo[2,3-b]Pyridine Derivatives Active as Kinase Inhibitors and Pharmaceutical Compositions Comprising Them | PFIZER ITALIA S.R.L. (IT) | 2010-08-19 | — | — | US | disclosed |
| US-7728140-B2 | Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2010-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210476-A1 | Pyrrolo[2,3-b]Pyridine Derivatives Active as Kinase Inhibitors and Pharmaceutical Compositions Comprising Them | MAP3K6, MAP3K3, MAP3K1 | MAP4K1 20/4885CYP3A4 3832/4885ABL1 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.